French Health Spending Deficit Down

25 May 1997

In France, the latest estimates by social security specialists indicatea deficit this year of some 35 billion French francs ($6.05 billion) compared with 54 billion francs in 1996, a distinct improvement on earlier government forecasts. Income is expected to improve as the active workforce grows 3.3%, adding an estimated 5 billion francs to contributions.

However, the figures remain wide of the government target of a 1997 surplus of 12 billion francs. 1996 health spending growth was contained at 3.3% to 600 billion francs, or a third of total social security spending, and this year it is forecast at only 1.7%, in the wake of constraints applied to doctors and the hospital sector.

Despite recent strikes and protest action, few observers believe that the health care professions will undermine current efforts at health service reform, while the hospitals face a total evaluation of their activities within the next five years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight